Because the combination with the downregulation of tumour suppressors and genes involved in cell proliferation is a candidate for synthetic lethality, cytoplasmic PRMT5/MEP50 may be a therapeutic target in NDRG2low cancers. Here, WDR77 is linked to cancer.